The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Safety and long-term maintenance of anti-HER2 immunity following booster inoculations of the E75 breast cancer vaccine.
Raetasha Sheavette Dabney
No relevant relationships to disclose
Diane F Hale
No relevant relationships to disclose
Timothy J Vreeland
No relevant relationships to disclose
Guy T. Clifton
No relevant relationships to disclose
Alan K. Sears
No relevant relationships to disclose
Ritesh Patil
No relevant relationships to disclose
Sathibalan Ponniah
No relevant relationships to disclose
Nathan M. Shumway
No relevant relationships to disclose
George Earl Peoples
Consultant or Advisory Role - Galena Biopharma (U); Owns part of IP patent for E75
Research Funding - Galena Biopharma
Elizabeth Ann Mittendorf
No relevant relationships to disclose